Boston hospitals to launch landmark genome study of newborns
Hundreds of Boston newborns will be enrolled in a landmark study that will sequence their entire genomes and evaluate the effect of DNA sequencing on their future medical care, and the relationship between the parents, the baby and baby’s pediatrician, Brigham and Women’s and Boston Children’s Hospital announced today.
Beginning in early 2014, the study — “the first-ever randomized trial” of the benefits and risks of such sequencing — will enroll 480 newborns and their parents, the hospitals said. The volunteers, healthy newborns from Brigham and Women’s Hospital and infants from Boston Children’s Hospital’s Neonatal Intensive Care Unit, will be divided into two groups. One group will receive conventional state-mandated newborn screening, the other will receive conventional screening and genome sequencing. Researchers will collect and analyze the genomic sequences, which may include information on potential causes of any birth defects, predispositions to future medical conditions and predictions about responses to certain drugs, and will return that information to parents and pediatricians to evaluate the medical, psychosocial and economic outcomes.
The study will last five years.
“These analyses will help illuminate the full spectrum of benefits and risks associated with genome sequencing of newborns,” said Alan Beggs, director of the Manton Center for Orphan Disease Research and a professor of pediatrics and scientist in the Division of Genetics at Boston Children’s Hospital.
A $6 million grant for the study was given to Brigham and Women’s and Boston Children’s Hospital by the National Institutes of Health.
Beginning in early 2014, the study — “the first-ever randomized trial” of the benefits and risks of such sequencing — will enroll 480 newborns and their parents, the hospitals said. The volunteers, healthy newborns from Brigham and Women’s Hospital and infants from Boston Children’s Hospital’s Neonatal Intensive Care Unit, will be divided into two groups. One group will receive conventional state-mandated newborn screening, the other will receive conventional screening and genome sequencing. Researchers will collect and analyze the genomic sequences, which may include information on potential causes of any birth defects, predispositions to future medical conditions and predictions about responses to certain drugs, and will return that information to parents and pediatricians to evaluate the medical, psychosocial and economic outcomes.
The study will last five years.
“These analyses will help illuminate the full spectrum of benefits and risks associated with genome sequencing of newborns,” said Alan Beggs, director of the Manton Center for Orphan Disease Research and a professor of pediatrics and scientist in the Division of Genetics at Boston Children’s Hospital.
A $6 million grant for the study was given to Brigham and Women’s and Boston Children’s Hospital by the National Institutes of Health.
Boston hospitals to launch landmark genome study of newborns
Hundreds of Boston newborns will be enrolled in a landmark study that will sequence their entire genomes and evaluate the effect of DNA sequencing on their future medical care, and the relationship between the parents, the baby and baby’s pediatrician, Brigham and Women’s and Boston Children’s Hospital announced today.
Beginning in early 2014, the study — “the first-ever randomized trial” of the benefits and risks of such sequencing — will enroll 480 newborns and their parents, the hospitals said. The volunteers, healthy newborns from Brigham and Women’s Hospital and infants from Boston Children’s Hospital’s Neonatal Intensive Care Unit, will be divided into two groups. One group will receive conventional state-mandated newborn screening, the other will receive conventional screening and genome sequencing. Researchers will collect and analyze the genomic sequences, which may include information on potential causes of any birth defects, predispositions to future medical conditions and predictions about responses to certain drugs, and will return that information to parents and pediatricians to evaluate the medical, psychosocial and economic outcomes.
The study will last five years.
“These analyses will help illuminate the full spectrum of benefits and risks associated with genome sequencing of newborns,” said Alan Beggs, director of the Manton Center for Orphan Disease Research and a professor of pediatrics and scientist in the Division of Genetics at Boston Children’s Hospital.
A $6 million grant for the study was given to Brigham and Women’s and Boston Children’s Hospital by the National Institutes of Health.
Beginning in early 2014, the study — “the first-ever randomized trial” of the benefits and risks of such sequencing — will enroll 480 newborns and their parents, the hospitals said. The volunteers, healthy newborns from Brigham and Women’s Hospital and infants from Boston Children’s Hospital’s Neonatal Intensive Care Unit, will be divided into two groups. One group will receive conventional state-mandated newborn screening, the other will receive conventional screening and genome sequencing. Researchers will collect and analyze the genomic sequences, which may include information on potential causes of any birth defects, predispositions to future medical conditions and predictions about responses to certain drugs, and will return that information to parents and pediatricians to evaluate the medical, psychosocial and economic outcomes.
The study will last five years.
“These analyses will help illuminate the full spectrum of benefits and risks associated with genome sequencing of newborns,” said Alan Beggs, director of the Manton Center for Orphan Disease Research and a professor of pediatrics and scientist in the Division of Genetics at Boston Children’s Hospital.
A $6 million grant for the study was given to Brigham and Women’s and Boston Children’s Hospital by the National Institutes of Health.
Boston hospitals to launch landmark genome study of newborns
Hundreds of Boston newborns will be enrolled in a landmark study that will sequence their entire genomes and evaluate the effect of DNA sequencing on their future medical care, and the relationship between the parents, the baby and baby’s pediatrician, Brigham and Women’s and Boston Children’s Hospital announced today.
Beginning in early 2014, the study — “the first-ever randomized trial” of the benefits and risks of such sequencing — will enroll 480 newborns and their parents, the hospitals said. The volunteers, healthy newborns from Brigham and Women’s Hospital and infants from Boston Children’s Hospital’s Neonatal Intensive Care Unit, will be divided into two groups. One group will receive conventional state-mandated newborn screening, the other will receive conventional screening and genome sequencing. Researchers will collect and analyze the genomic sequences, which may include information on potential causes of any birth defects, predispositions to future medical conditions and predictions about responses to certain drugs, and will return that information to parents and pediatricians to evaluate the medical, psychosocial and economic outcomes.
The study will last five years.
“These analyses will help illuminate the full spectrum of benefits and risks associated with genome sequencing of newborns,” said Alan Beggs, director of the Manton Center for Orphan Disease Research and a professor of pediatrics and scientist in the Division of Genetics at Boston Children’s Hospital.
A $6 million grant for the study was given to Brigham and Women’s and Boston Children’s Hospital by the National Institutes of Health.
Beginning in early 2014, the study — “the first-ever randomized trial” of the benefits and risks of such sequencing — will enroll 480 newborns and their parents, the hospitals said. The volunteers, healthy newborns from Brigham and Women’s Hospital and infants from Boston Children’s Hospital’s Neonatal Intensive Care Unit, will be divided into two groups. One group will receive conventional state-mandated newborn screening, the other will receive conventional screening and genome sequencing. Researchers will collect and analyze the genomic sequences, which may include information on potential causes of any birth defects, predispositions to future medical conditions and predictions about responses to certain drugs, and will return that information to parents and pediatricians to evaluate the medical, psychosocial and economic outcomes.
The study will last five years.
“These analyses will help illuminate the full spectrum of benefits and risks associated with genome sequencing of newborns,” said Alan Beggs, director of the Manton Center for Orphan Disease Research and a professor of pediatrics and scientist in the Division of Genetics at Boston Children’s Hospital.
A $6 million grant for the study was given to Brigham and Women’s and Boston Children’s Hospital by the National Institutes of Health.
.png)
No hay comentarios:
Publicar un comentario